ITI 4000
Alternative Names: ITI-4000Latest Information Update: 28 Feb 2024
At a glance
- Originator Immunomic Therapeutics
- Class Cancer vaccines; DNA vaccines; Immunotherapies
- Mechanism of Action CD4-positive T-lymphocyte stimulants; CD8 positive T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Gastric cancer; Nasopharyngeal cancer
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for preclinical development in Nasopharyngeal-cancer in USA (Intratumoural)
- 28 Jun 2023 No recent reports of development identified for research development in Gastric-cancer in USA (Intratumoural)
- 29 Jan 2020 ITI 4000 is available for licensing as of 29 Jan 2020. https://www.immunomix.com/partnerships/